Novo Nordisk Loses Appeal on Human Growth Hormone Patent Suit

Drug Industry Daily
KEYWORDS courts
A A

Novo Nordisk Pharmaceuticals has lost a challenge in the U.S. Court of Appeals for the Federal Circuit to overturn a lower court ruling that part of Novo’s patent on its human growth hormone (HGH) Norditropin (somatropin recombinant) was invalid and unenforceable due to inequitable conduct. While Novo has partially settled its lawsuit with defendants Savient and Teva Pharmaceutical, the decision keeps the door open to generic versions of Novo’s product.

To View This Article:

Login

Subscribe To Drug Industry Daily